Restricted accessResearch articleFirst published online 2011-10
Disruption of Hypoxia-Inducible Transcription Factor-Prolyl Hydroxylase Domain-1 (PHD-1 −/− ) Attenuates Ex Vivo Myocardial Ischemia/Reperfusion Injury Through Hypoxia-Inducible Factor-1α Transcription Factor and Its Target Genes in Mice
Hypoxia-inducible transcription factor (HIF)-prolyl hydroxylases domain (PHD-1–3) are oxygen sensors that regulate the stability of the HIFs in an oxygen-dependent manner. Suppression of PHD enzymes leads to stabilization of HIFs and offers a potential treatment option for many ischemic disorders, such as peripheral artery occlusive disease, myocardial infarction, and stroke. Here, we show that homozygous disruption of PHD-1 (PHD-1−/−) could facilitate HIF-1α-mediated cardioprotection in ischemia/reperfused (I/R) myocardium. Wild-type (WT) and PHD-1−/− mice were randomized into WT time-matched control (TMC), PHD-1−/− TMC (PHD1TMC), WT I/R, and PHD-1−/− I/R (PHD1IR). Isolated hearts from each group were subjected to 30 min of global ischemia followed by 2 h of reperfusion. TMC hearts were perfused for 2 h 30 min without ischemia. Decreased infarct size (35% ± 0.6% vs. 49% ± 0.4%) and apoptotic cardiomyocytes (106 ± 13 vs. 233 ± 21 counts/100 high-power field) were observed in PHD1IR compared to wild-type ischemia/reperfusion (WTIR). Protein expression of HIF-1α was significantly increased in PHD1IR compared to WTIR. mRNA expression of β-catenin (1.9-fold), endothelial nitric oxide synthase (1.9-fold), p65 (1.9-fold), and Bcl-2 (2.7-fold) were upregulated in the PHD1IR compared with WTIR, which was studied by real-time quantitative polymerase chain reaction. Further, gel-shift analysis showed increased DNA binding activity of HIF-1α and nuclear factor-kappaB in PHD1IR compared to WTIR. In addition, nuclear translocation of β-catenin was increased in PHD1IR compared with WTIR. These findings indicated that silencing of PHD-1 attenuates myocardial I/R injury probably by enhancing HIF-1α/β-catenin/endothelial nitric oxide synthase/nuclear factor-kappaB and Bcl-2 signaling pathway. Antioxid. Redox Signal. 15, 1789–1797.
Get full access to this article
View all access options for this article.
References
1.
AragonesJ, SchneiderM, Van GeyteK, FraislP, DresselaersT, MazzoneM, DirkxR, ZacchignaS, LemieuxH, JeoungNH, LambrechtsD, BishopT, LafusteP, Diez-JuanA, HartenSK, Van NotenP, De BockK, WillamC, TjwaM, GrosfeldA, NavetR, MoonsL, VandendriesscheT, DerooseC, WijeyekoonB, NuytsJ, JordanB, Silasi-MansatR, LupuF, DewerchinM, PughC, SalmonP, MortelmansL, GallezB, GorusF, BuyseJ, SluseF, HarrisRA, GnaigerE, HespelP, Van HeckeP, SchuitF, Van VeldhovenP, RatcliffeP, BaesM, MaxwellP, CarmelietP. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet, 40:170–180. 2008.
2.
BaoW, QinP, NeedleS, Erickson-MillerCL, DuffyKJ, AriaziJL, ZhaoS, OlzinskiAR, BehmDJ, PipesGC, JuckerBM, HuE, LeporeJJ, WilletteRN. Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat. J Cardiovasc Pharmacol, 56:147–155. 2010.
3.
BaranovaO, MirandaLF, PichiuleP, DragatsisI, JohnsonRS, ChavezJC. Neuron-specific inactivation of the hypoxia inducible factor 1 alpha increases brain injury in a mouse model of transient focal cerebral ischemia. J Neurosci, 27:6320–6332. 2007.
4.
EckleT, KohlerD, LehmannR, El KasmiK, EltzschigHK. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation, 118:166–175. 2008.
5.
FoadoddiniM, EsmailidehajM, MehraniH, SadraeiSH, GolmaneshL, WahhabaghaiH, ValenG, KhoshbatenA. Pretreatment with hyperoxia reduces in vivo infarct size and cell death by apoptosis with an early and delayed phase of protection. Eur J Cardiothorac Surg, 39:233–240. 2011.
6.
FraislP, AragonesJ, CarmelietP. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov, 8:139–152. 2009.
7.
HirotaK, SemenzaGL. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol, 59:15–26. 2006.
8.
HyvarinenJ, HassinenIE, SormunenR, MakiJM, KivirikkoKI, KoivunenP, MyllyharjuJ. Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury. J Biol Chem, 285:13646–13657. 2010.
9.
JiangM, WangB, WangC, HeB, FanH, GuoTB, ShaoQ, GaoL, LiuY. Angiogenesis by transplantation of HIF-1 alpha modified EPCs into ischemic limbs. J Cell Biochem, 103:321–334. 2008.
10.
JonesSP, GirodWG, PalazzoAJ, GrangerDN, GrishamMB, Jourd'HeuilD, HuangPL, LeferDJ. Myocardial ischemia-reperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthase. Am J Physiol, 276:H1567–H1573. 1999.
11.
JonesSP, GreerJJ, KakkarAK, WarePD, TurnageRH, HicksM, van HaperenR, de CromR, KawashimaS, YokoyamaM, LeferDJ. Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol, 286:H276–H282. 2004.
12.
KatschinskiDM. In vivo functions of the prolyl-4-hydroxylase domain oxygen sensors: direct route to the treatment of anaemia and the protection of ischaemic tissues. Acta Physiol (Oxf), 195:407–414. 2009.
MalhotraR, TysonDW, RosevearHM, BrosiusFC3rd. Hypoxia-inducible factor-1alpha is a critical mediator of hypoxia induced apoptosis in cardiac H9c2 and kidney epithelial HK-2 cells. BMC Cardiovasc Disord, 8:9. 2008.
15.
MoensAL, ClaeysMJ, TimmermansJP, VrintsCJ. Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol, 100:179–190. 2005.
16.
Munoz-ChapuliR, QuesadaAR, Angel MedinaM. Angiogenesis and signal transduction in endothelial cells. Cell Mol Life Sci, 61:2224–2243. 2004.
17.
NapoliC, IgnarroLJ. Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Arch Pharm Res, 32:1103–1108. 2009.
18.
NatarajanR, SalloumFN, FisherBJ, OwnbyED, KukrejaRC, FowlerAA3rd. Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium. Am J Physiol Heart Circ Physiol, 293:H1571–H1580. 2007.
OckailiR, NatarajanR, SalloumF, FisherBJ, JonesD, FowlerAA3rd, KukrejaRC. HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation. Am J Physiol Heart Circ Physiol, 289:H542–H548. 2005.
21.
ParkS, ChoiJ. Inhibition of beta-catenin/Tcf signaling by flavonoids. J Cell Biochem, 110:1376–1385. 2010.
22.
PhilippS, JurgensenJS, FielitzJ, BernhardtWM, WeidemannA, SchicheA, PilzB, DietzR, Regitz-ZagrosekV, EckardtKU, WillenbrockR. Stabilization of hypoxia inducible factor rather than modulation of collagen metabolism improves cardiac function after acute myocardial infarction in rats. Eur J Heart Fail, 8:347–354. 2006.
23.
RomashkovaJA, MakarovSS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature, 401:86–90. 1999.
24.
SamuelSM, AkitaY, PaulD, ThirunavukkarasuM, ZhanL, SudhakaranPR, LiC, MaulikN. Coadministration of adenoviral vascular endothelial growth factor and angiopoietin-1 enhances vascularization and reduces ventricular remodeling in the infarcted myocardium of type 1 diabetic rats. Diabetes, 59:51–60. 2010.
25.
SamuelSM, ThirunavukkarasuM, PenumathsaSV, KoneruS, ZhanL, MaulikG, SudhakaranPR, MaulikN. Thioredoxin-1 gene therapy enhances angiogenic signaling and reduces ventricular remodeling in infarcted myocardium of diabetic rats. Circulation, 121:1244–1255. 2010.
26.
SamuelSM, ThirunavukkarasuM, PenumathsaSV, PaulD, MaulikN. Akt/FOXO3a/SIRT1-mediated cardioprotection by n-tyrosol against ischemic stress in rat in vivo model of myocardial infarction: switching gears toward survival and longevity. J Agric Food Chem, 56:9692–9698. 2008.
27.
SasakiH, RayPS, ZhuL, OtaniH, AsaharaT, MaulikN. Hypoxia/reoxygenation promotes myocardial angiogenesis via an NF kappa B-dependent mechanism in a rat model of chronic myocardial infarction. J Mol Cell Cardiol, 33:283–294. 2001.
28.
SasakiH, ZhuL, FukudaS, MaulikN. Inhibition of NF kappa B activation by pyrrolidine dithiocarbamate prevents in vivo hypoxia/reoxygenation-mediated myocardial angiogenesis. Int J Tissue React, 22:93–100. 2000.
29.
SchneiderM, Van GeyteK, FraislP, KissJ, AragonesJ, MazzoneM, MairbaurlH, De BockK, JeoungNH, MollenhauerM, GeorgiadouM, BishopT, RoncalC, SutherlandA, JordanB, GallezB, WeitzJ, HarrisRA, MaxwellP, BaesM, RatcliffeP, CarmelietP. Loss or silencing of the PHD1 prolyl hydroxylase protects livers of mice against ischemia/reperfusion injury. Gastroenterology, 138:1143–1154e1-22010.
30.
SiddiqA, AyoubIA, ChavezJC, AminovaL, ShahS, LaMannaJC, PattonSM, ConnorJR, ChernyRA, VolitakisI, BushAI, LangsetmoI, SeeleyT, GunzlerV, RatanRR. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem, 280:41732–41743. 2005.
31.
TakedaK, HoVC, TakedaH, DuanLJ, NagyA, FongGH. Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol, 26:8336–8346. 2006.
32.
TekinD, DursunAD, XiL. Hypoxia inducible factor 1 (HIF-1) and cardioprotection. Acta Pharmacol Sin, 31:1085–1094. 2010.
33.
ThirunavukkarasuM, AddyaS, JuhaszB, PantR, ZhanL, SurreyS, MaulikG, MenonVP, MaulikN. Heterozygous disruption of Flk-1 receptor leads to myocardial ischaemia reperfusion injury in mice: application of affymetrix gene chip analysis. J Cell Mol Med, 12:1284–1302. 2008.
34.
ThirunavukkarasuM, HanZ, ZhanL, PenumathsaSV, MenonVP, MaulikN. Adeno-sh-beta-catenin abolishes ischemic preconditioning-mediated cardioprotection by downregulation of its target genes VEGF, Bcl-2, and survivin in ischemic rat myocardium. Antioxid Redox Signal, 10:1475–1484. 2008.
35.
ThirunavukkarasuM, JuhaszB, ZhanL, MenonVP, TosakiA, OtaniH, MaulikN. VEGFR1 (Flt-1 + /-) gene knockout leads to the disruption of VEGF-mediated signaling through the nitric oxide/heme oxygenase pathway in ischemic preconditioned myocardium. Free Radic Biol Med, 42:1487–1495. 2007.
36.
VincentKA, FeronO, KellyRA. Harnessing the response to tissue hypoxia: HIF-1 alpha and therapeutic angiogenesis. Trends Cardiovasc Med, 12:362–367. 2002.
37.
WangY, SunA, XueJ, FengC, LiJ, WuJ. Bone marrow derived stromal cells modified by adenovirus-mediated HIF-1alpha double mutant protect cardiac myocytes against CoCl2-induced apoptosis. Toxicol In Vitro, 23:1069–1075. 2009.
38.
YuanY, HilliardG, FergusonT, MillhornDE. Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J Biol Chem, 278:15911–15916. 2003.
39.
ZhouYF, ZhengXW, ZhangGH, ZongZH, QiGX. The effect of hypoxia-inducible factor 1-alpha on hypoxia-induced apoptosis in primary neonatal rat ventricular myocytes. Cardiovasc J Afr, 21:37–41. 2010.
